

TO: DDG: Chief of Operations

Chief Directors: MHS, RHS, Strategy

Heads of Institutions

District & Sub-Structure Directors

Director: City Health

Circular H18 /2022

COVID-19 PROJECT OFFICE: CHANGES TO DOSING INTERVALS AND INTRODUCTION OF HETEROLOGOUS BOOSTER DOSES NATIONAL VACCINATION PROGRAMME CIRCULAR 2 OF 2022

Kindly note the attached circular for implementation as follows:

1. Changes to dosing intervals for Cominarty® (Pfizer) primary vaccinations – effective 23 Feb 2022

2. Introduction of heterologous booster doses: effective 21 & 23 Feb 2022

- Note that the dates for Janssen® (J&J) & Cominarty® (Pfizer) differ.

Details contained in the attachment.

Yours sincerely



Chief Director: ECSS Date: 22 Feb 2022



DIRECTOR GENERAL HEALTH REPUBLIC OF SOUTH AFRICA

PRETORIA Private Bag X828, PRETORIA, 0001, Dr AB Xuma Building, 1112 Voortrekker Rd, Pretoria 351-JR, Pretoria, 0187, Tel (012) 395 8402 CAPE TOWN P.O. Box 3875, CAPE TOWN, 8000, 103 Parliament Towers, Room 615, 20 Plain Street, CAPE TOWN, 8000 Tel (021) 461 2040 Fax (021) 461 6864

TO: HEADS OF PROVINCIAL HEALTH DEPARTMENTS DISTRICT, HOSPITAL AND PHC MANAGERS COVID-19 VACCINE PROGRAMME MANAGERS COVID-19 VACCINATION SITE MANAGERS COVID-19 VACCINATORS

NATIONAL VACCINATION PROGRAMME CIRCULAR 2 OF 2022

CHANGES TO DOSING INTERVALS AND INTRODUCTION OF HETEROLOGOUS BOOSTER DOSES

Changes to dosing intervals for Cominarty® vaccine

 From Wednesday, 23rd February 2022, the interval between the first and second doses of the Cominarty[®] (Pfizer) vaccine will be reduced from 42 days to 21 days. Furthermore, individuals will be eligible to receive a booster dose 90 days (three months) after receiving the second dose of the vaccine (reduced from 180 days).

Introduction of heterologous booster doses

- The circular "Provision of booster doses of Covid vaccines" issued on 23rd December 2021 makes provision for administration of homologous booster doses of COVID vaccines. This circular provides for administration of **heterologous booster doses** i.e. booster doses of a different vaccine to that which was administered as the primary series.
- 3. From Monday, 21st February 2022 individuals older than 18 years of age who have received one dose of the COVID-19 vaccine Janssen[®] (J&J) will be eligible to receive a booster dose of the same vaccine or a booster dose of Cominarty[®] vaccine after an interval of two months (60 days).
- 4. From Wednesday, 23rd February 2022, individuals over the age of 18 years who have received two doses of the Cominarty[®] (Pfizer) vaccine will be eligible to receive a booster dose of the same vaccine or a booster dose of the COVID-19 vaccine Janssen[®]. In line with paragraph 1 above, individuals will be eligible to receive the booster dose 90 days (three months) after receiving the second of the two doses of the Cominarty[®] vaccine.

- 5. The decision regarding which vaccine to administer as a booster should be guided by vaccine availability. If both vaccines are available, homologous boosting should be preferred, unless the vaccinee requests to receive a heterologous booster dose, or has a history of experiencing an adverse event following immunisation. (Please remember that all adverse events following immunisation must be reported).
- 6. From Wednesday 23rd February, the vaccination schedules will therefore be as follows:

Primary Schedule			Deseter	
First dose		Second dose	Booster	
Cominarty [®] Vaccine	Minimum of 21 day interval	Cominarty [®] Vaccine	Minimum of 90 day interval	Cominarty [®] Vaccine OR COVID-19 vaccine Janssen [®]

OR

Primary Schedule One dose	Booster	
COVID-19 vaccine Janssen®	Minimum of 60 day interval	COVID-19 vaccine Janssen [®] OR Cominarty [®] Vaccine

- 7. All booster doses must be recorded on the EVDS.
- 8. The EVDS is being updated so that individuals who did not receive their primary COVID vaccinations in South Africa, but are eligible to receive a booster dose, can be registered on the EVDS and receive the booster dose. More information regarding the date at which the functionality to record such doses on the EVDS will be available will be provided. Once the functionality is available on the EVDS, the vaccination of such individuals should proceed.

DR SSS BUTHELEZI DIRECTOR-GENERAL: HEALTH DATE: 20/02/2022